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Sir, The increasing problem of multidrug-resistant Gram-positive and Gram-negative bacteria causing severe infections has led to a re-evaluation of old drugs and the application of newly developed reserve antibiotics.
Polymyxins and chloramphenicol were discovered in 1947. Both drugs were gradually withdrawn from clinical practice in Europe and the USA because of reports about toxicity. However, the emergence of Pseudomonas aeruginosa and Acinetobacter baumannii strains that are resistant to almost all available antibiotics has led to a revival of polymyxins given parenterally. Chloramphenicol is still prescribed to a majority of the populations in developing countries because of its low cost of production and its broad spectrum. Fosfomycin, which was discovered in 1969, is effective against numerous Gram-positive and Gram-negative bacteria and acts synergistically against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and multiresistant P. aeruginosa strains. 2 Quinupristin/dalfopristin, linezolid and tigecycline are considered to be new antibiotics with a spectrum that also covers multiresistant pathogens; they were approved by the FDA in Although in recent years data on antibiotic use have become available from surveillance systems such as European Surveillance of Antimicrobial Consumption (ESAC), there are no multicentre data on the consumption of reserve antibiotics. 4 The aim of our study was to provide such data for intensive care units (ICUs), which are known high-risk areas for resistant pathogens.
Data from 44 ICUs in Germany participating in the project Surveillance of Antimicrobial Use and Resistance in ICUs (SARI) were analysed from 2001 through 2006. 5 Consumption was measured as antimicrobial usage density (AD) and expressed as defined daily doses (DDD) and normalized per 1000 patient-days ( pd), one DDD being the standard adult daily dose of an antimicrobial agent for 1 day of treatment defined by the WHO (by DDD index 2006). SARI collects data on 13 pathogens including MRSA, VRE, imipenem-resistant P. aeruginosa and Escherichia coli resistant to third-generation cephalosporins. Isolates documented were non-duplicate. Consumption of old antibiotics, i.e. amphenicols, polymyxins ( parenteral or for inhalation) and fosfomycin, proved to be fairly stable over a period of 6 years and constituted 0. Old antibiotics such as fosfomycin, with a consumption of 6.6 DDD/1000 pd in 2006, accounted for ,1% of total antibiotic consumption. Use did not increase over time.
Although there are reports on multi-or even pan-resistance evolving in P. aeruginosa, A. baumannii and K. pneumoniae, and a revival of polymyxins applied parenterally or by inhalation, they were not used in 2006 in 41 German ICUs. 6 However, it has to be taken into account that in SARI no data are available on multiresistance. Furthermore, these data might only reflect the situation in German ICUs. ICUs might differ in other European regions with a different resistance situation.
This study reports data on use of linezolid, quinupristin/ dalfopristin, tigecycline, polymyxins, amphenicols and fosfomycin and provides benchmarking data on these reserve antimicrobials for use in ICUs.
